ORAMED PHARMACEUTICALS INC.
Form FWP
June 17, 2013

Breakthrough
Technology
for a
Brighter Future
1
Issuer Free Writing Prospectus
Filed Pursuant to Rule 433
Registration No. 333-187343
June 17, 2013

2

Safe Harbor

Certain statements contained in this material are forward-looking statements. These forward-looking statements are based on the current expectations of the management of Oramed only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for our product candidates; competition from other pharmaceutical or biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities, and others, all of which could cause the actual results or performance of Oramed to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Oramed undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Oramed, reference is made to Oramed's reports filed from time to time with the Securities and Exchange Commission. which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Please refer to the company's filings with the Securities and Exchange Commission for a comprehensive list of risk factors that could cause actual results, performance or achievements of the company to differ materially from those expressed or implied in such forward-looking statements. Oramed undertakes no obligation to update or revise any forward-looking statements.

Free Writing Prospectus Statement

This presentation highlights basic information about us and the offering. Because it is a summary, it does not contain all of the information that you should consider before investing.

We have filed a registration statement (including a prospectus dated March 22, 2013 and a preliminary prospectus supplement dated June 17, 2013) with the SEC for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement, the related preliminary prospectus supplement and other documents we have filed with the SEC for more complete information about us and this offering. You may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov. Alternatively, we, any underwriter or any dealer participating in the offering will arrange to send you the prospectus and preliminary prospectus supplement if you request it by calling Aegis Capital Corp., Prospectus Department, 810 Seventh Avenue, 18th Floor, New York, NY 10019, telephone: 212-813-1010, e-mail: prospectus@aegiscap.com or Maxim Group LLC, 405 Lexington Avenue, 2nd Floor, New York, NY 10174, toll-free telephone: 1-800-724-0761

3

Offering Summary	
Issuer	Oramed Pharmaceuticals Inc.
Exchange / Ticker	NASDAQ Capital Market / ORMP
Offering Size	Approximately $13 million (100% Primary)
Over-allotment	15% (100% Primary)
Use of Proceeds	Clinical development of ORMD-0801 and ORMD-0901, working capital & general corporate purposes
Book-Runners	Aegis Capital Corp and Maxim Group LLC

Oramed
An oral solution….
5

6
Oramed Overview

Protein breakdown, low bioavailability
Harsh pH
Protease
threat
Mechanical
challenges
Absorption
barrier
Fate of proteins/peptides in GIT
7

Oramed Technology:
Oramed's delivery platform protects proteins and enhances their absorption, allowing them to reach the bloodstream via the portal vein, thereby establishing a more physiologic protein gradient when compared to other delivery systems.

Versatile
Simple
Competent
Versatile
Supports a
wide range
of protein
sizes and
doses
Simple
Simple
blend of
ingredients
ORAMED DRUG DELIVERY

Regulatory competence
No NCEs; widely applied
pharmacopoeia
9
Oramed Technology

10
Diabetes:
A Global Epidemic


Type 2 Diabetes: A Global Epidemic
• $471 billion: Estimated total annual economic cost of diabetes worldwide (IDF, 2012)
• $14.5 billion: Estimated total global insulin market (ReportLinker, 2010)
11
350
0
50
100
150
200
250
300
1985
2000
2012
Year
http://www.idf.org/home/
171 Million
30 Million
371 Million
(IDF Diabetes Atlas, 2012)
400
Type 2 diabetes accounts for 85-95% of diabetes cases

Pipeline Overview

Therapy	Indication	Preclinical	Phase I	Phase II (ex-US)	Phase II (FDA)	Timeline
ORMD - 0801	T2DM					Q3, ‘13: Phase IIa “sub-study” projected initiation Q2, ’14: Phase IIb multi-center study projected initiation
	T1DM					Q2, ‘14: Phase II (ex-US) multi-center trial projected initiation
ORMD-0901	T2DM					Q1 ’13: Phase I/II (ex-US) study initiated
Combination Therapy	T2DM					Q1, ‘13: First-in-human PoC trial initiated

13
ORMD-0801
Oral Insulin

Total number of study subjects: 131
Total number of administrations in humans: 1444
38
27
66

15
ORMD-0801
Type 2 Diabetes

16

l Blood glucose - insulin secretion system forms a 'closed-loop'

l Peripheral insulin promotes glucose uptake in fat and muscle

l First-pass hepatic metabolism extracts 80% of secreted insulin

l Systemic exposure is minimized

Portal insulin delivery is physiologic.

Systemic insulin delivery is not.

pancreas

portal vein

liver

17

Initial Treatment:

• Lifestyle Modification

• Diet & Exercise

Single & Combination Oral Therapies:

• ORMD-0801

• Reduce insulin resistance

• Stimulate insulin secretion

Final Treatment:

• Insulin Replacement

ORMD-0801 is not a substitute for insulin injections, but rather a new earlier treatment option

Stages of Type 2 Diabetes

Criteria for advancing to next stage:

AIC not at target < 7.0%

Type 2 Diabetes:

Stages & Treatment Options

ORMD-0801 Pre-clinical
19

Healthy, non-diabetic, cannulated beagle dogs 60-75% drop in blood glucose levels within 30-100 minutes of treatment
No hypoglycemia or adverse events were observed over the three years of testing
0
20
40
60
80
0
60
120
180
Time (min)
n=4
8 mg insulin
8 mg insulin, no additives
1.5 U NovoRapid
ORMD-0801 (A)
ORMD-0801 (C)
20
ORMD-0801
Preclinical - Dogs

20
40
60
80
-
0
30
60
90
120
NC
0
100
-
10
150
Time (min)
NC; 4 independent test sessions
Fasting
n=2
Pre-
prandial
0
20
40
60
80
100
120
140
0
50
100
150
Time (min)
-20
n=3
NC; 6 independent test sessions
ORMD-0801; 5 independent sessions
8 mg
insulin
21
ORMD-0801
Preclinical - Pigs

Phase II Study (ex-US):
Design: Multi-centered, placebo-controlled, randomized, double-blinded, 29 T2DM patient study to evaluate safety and tolerability of one bedtime orally administered ORMD-0801 formulation (2 capsules containing 8 mg insulin each) as well as its effectiveness in providing glycemic control.
21 T2DM
8 T2DM
Monitor safety parameters
Compare plasma markers at start of study to those at end of study
ORMD-0801
once daily
placebo
once daily
22

T2DM Clinical Results
23

Results:

Safety:

• First extended exposure to ORMD-0801 proved safe and tolerable.

• No serious adverse events reported.

• No cumulative effects were observed.

• Only two hypoglycemic events were recorded - both were mild.

Efficacy:

• Reduced glycemia & inflammatory markers

• Percentage of patients demonstrating clinically relevant reductions in insulin, c-peptide, fasting blood glucose (FBG), and Hb1Ac levels was higher in the ORMD-0801 cohort, compared to the placebo.

0

5

10

15

20

25

30

35

40

45

50

FBG

Fructose-
amine

HbA1c

Insulin

c-peptide

CRP

ORMD-0801

Placebo

Phase II Study (ex-US):

FBG, HbA1c, Cardiovascular Disease Risk,
Hypoglycemia

24

Upcoming Trial
(under FDA IND)
25

26
ORMD-0801
Type 1 Diabetes

ID:
8
80
100
120
140
160
-10
-5
0
5
10
15
200
240
300
360
180
Time (min)
ID:
9
70
120
170
220
270
-14
-10
-6
-2
0
200
240
300
360
180
Time (min)
Expected rate of increase in fasting blood glucose concentrations among T1DM upon insulin withdrawal: 45.1 ± 9.7 mg/dL·hr-1 (Clement et al, 2002, Diabetes Technol Ther 4(4):459)

Identity of Issuer, Borrower, Lessor, or Similar Party	Description of Investment, Including Maturity Date, Rate of Interest,	Current Value

		Collateral, Par, or Maturity Value
Participant notes receivable*	Interest rates ranging from 4.25% to 11.0% with various maturity dates	$ 8,071,373

* Indicates party in interest to the Plan.

Table of Contents

SIGNATURES

The Plan. Pursuant to the requirements of the Securities Exchange Act of 1934, the trustees (or other person who administer the employee benefit plan) have duly caused this annual report to be signed on its behalf by the undersigned hereunto duly authorized.

THE HOURLY PENSION INVESTMENT PLAN

Date: June 25, 2010

By: /s/ Scott A. Scherff
Scott A. Scherff
Assistant Secretary